The antiinfective medicine sales in Norway stood at 2.86 billion Norwegian Krones in 2023. In the coming years, starting from 2024, the forecasted sales values are expected to increase from 2.97 billion Norwegian Krones in 2024 to 3.43 billion Norwegian Krones by 2028. This demonstrates a consistent year-on-year growth, showcasing percentage variations of approximately:
- 3.8% from 2024 to 2025
- 3.9% from 2025 to 2026
- 3.4% from 2026 to 2027
- 3.6% from 2027 to 2028
Over the five-year span from 2023 to 2028, the compound annual growth rate (CAGR) stands around 3.6%, indicating steady and sustained growth in the antiinfective medicine market in Norway.
Future trends to watch include the potential impact of emerging new drug therapies, developments in antibiotic resistance, and government policies on healthcare spending which might influence the market dynamics and growth trajectory in the coming years.
